X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Natco Pharma with Aventis Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NATCO PHARMA vs SANOFI INDIA - Comparison Results

SANOFI INDIA 
   Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NATCO PHARMA SANOFI INDIA NATCO PHARMA/
SANOFI INDIA
 
P/E (TTM) x 34.4 31.0 111.0% View Chart
P/BV x 17.5 5.5 320.1% View Chart
Dividend Yield % 0.7 1.6 39.6%  

Financials

 NATCO PHARMA   SANOFI INDIA
EQUITY SHARE DATA
    NATCO PHARMA
Mar-14
SANOFI INDIA
Dec-16
NATCO PHARMA/
SANOFI INDIA
5-Yr Chart
Click to enlarge
High Rs8774,560 19.2%   
Low Rs4244,400 9.6%   
Sales per share (Unadj.) Rs223.41,028.5 21.7%  
Earnings per share (Unadj.) Rs31.1129.0 24.1%  
Cash flow per share (Unadj.) Rs40.3186.0 21.7%  
Dividends per share (Unadj.) Rs5.0068.00 7.4%  
Dividend yield (eoy) %0.81.5 50.7%  
Book value per share (Unadj.) Rs219.5753.6 29.1%  
Shares outstanding (eoy) m33.0723.03 143.6%   
Bonus/Rights/Conversions PA--  
Price / Sales ratio x2.94.4 66.8%   
Avg P/E ratio x20.934.7 60.3%  
P/CF ratio (eoy) x16.124.1 67.0%  
Price / Book Value ratio x3.05.9 49.8%  
Dividend payout %16.152.7 30.5%   
Avg Mkt Cap Rs m21,504103,174 20.8%   
No. of employees `000NA3.6 0.0%   
Total wages/salary Rs m1,1283,592 31.4%   
Avg. sales/employee Rs ThNM6,537.7-  
Avg. wages/employee Rs ThNM991.4-  
Avg. net profit/employee Rs ThNM819.8-  
INCOME DATA
Net Sales Rs m7,38923,686 31.2%  
Other income Rs m167708 23.6%   
Total revenues Rs m7,55624,394 31.0%   
Gross profit Rs m1,7935,281 34.0%  
Depreciation Rs m3041,313 23.2%   
Interest Rs m36615 2,441.3%   
Profit before tax Rs m1,2904,661 27.7%   
Minority Interest Rs m460-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3091,691 18.3%   
Profit after tax Rs m1,0272,970 34.6%  
Gross profit margin %24.322.3 108.9%  
Effective tax rate %23.936.3 66.0%   
Net profit margin %13.912.5 110.9%  
BALANCE SHEET DATA
Current assets Rs m3,68115,673 23.5%   
Current liabilities Rs m3,1236,678 46.8%   
Net working cap to sales %7.638.0 19.9%  
Current ratio x1.22.3 50.2%  
Inventory Days Days8976 117.8%  
Debtors Days Days5922 263.0%  
Net fixed assets Rs m7,6858,098 94.9%   
Share capital Rs m331230 143.6%   
"Free" reserves Rs m6,67017,088 39.0%   
Net worth Rs m7,25917,356 41.8%   
Long term debt Rs m9550-   
Total assets Rs m11,95725,400 47.1%  
Interest coverage x4.5311.7 1.5%   
Debt to equity ratio x0.10-  
Sales to assets ratio x0.60.9 66.3%   
Return on assets %11.711.8 99.2%  
Return on equity %14.217.1 82.7%  
Return on capital %20.726.9 76.9%  
Exports to sales %39.424.5 160.7%   
Imports to sales %5.728.0 20.4%   
Exports (fob) Rs m2,9085,801 50.1%   
Imports (cif) Rs m4216,627 6.4%   
Fx inflow Rs m3,4457,145 48.2%   
Fx outflow Rs m7036,846 10.3%   
Net fx Rs m2,743299 917.3%   
CASH FLOW
From Operations Rs m1,4403,226 44.6%  
From Investments Rs m-1,089-1,555 70.0%  
From Financial Activity Rs m-353-1,818 19.4%  
Net Cashflow Rs m-1-147 1.0%  

Share Holding

Indian Promoters % 52.0 0.0 -  
Foreign collaborators % 1.5 60.4 2.4%  
Indian inst/Mut Fund % 7.8 14.4 54.4%  
FIIs % 16.6 14.6 113.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 26.0 10.5 247.6%  
Shareholders   25,395 15,184 167.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NATCO PHARMA With:   PANACEA BIOTECH  DISHMAN PHARMA  TTK HEALTHCARE  JUBILANT LIFE SCIENCES  DIVIS LABORATORIES  

Compare NATCO PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Finishes on a Strong Note; Tata Global Beverages Surges 8.3%(Closing)

Indian share markets snapped their losing streak of last week and finished the trading day on a strong note due to strong buying momentum in FMCG stocks, metal stocks and auto stocks.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

Proxy Plays: A Smart Way to Bet on 'Off Limits' Companies(The 5 Minute Wrapup)

Aug 4, 2017

The small-cap space is full of small players that are clear proxies to great growth stories and Indian megatrends.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

NATCO PHARMA SHARE PRICE


Aug 16, 2017 (Close)

TRACK NATCO PHARMA

  • Track your investment in NATCO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NATCO PHARMA - ELDER PHARMA COMPARISON

COMPARE NATCO PHARMA WITH

MARKET STATS